Race Presents Mechanism of Action Data at ESMO 2025
Filed with ASX · · 3 pages · English
Earlier from Racura Oncology
- Discovery of the Anticancer Mechanism of (EE)-bisantrene
- RC220 IND Approval from Korean MFDS
- Race Breakthrough Composition of Matter IP Discovery
- First Hong Kong Site Activated for RC220 Trial
- Appendix 4E & Annual Report
Later from Racura Oncology
- September 2025 Quarterly Activity Report and Appendix 4C
- Race Clinical Program Update
- HARNESS1 Lung Cancer Trial Receives Human Ethics Approval
- Race Receives $2.8m RD Tax Refund
- Race Oncology Completes $3.22m Private Placement
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology